186 related articles for article (PubMed ID: 20053143)
1. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
2. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
Eisen T; Hedlund G; Forsberg G; Hawkins R
Curr Oncol Rep; 2014 Feb; 16(2):370. PubMed ID: 24445502
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis.
Hawkins RE; Gore M; Shparyk Y; Bondar V; Gladkov O; Ganev T; Harza M; Polenkov S; Bondarenko I; Karlov P; Karyakin O; Khasanov R; Hedlund G; Forsberg G; Nordle Ö; Eisen T
Clin Cancer Res; 2016 Jul; 22(13):3172-81. PubMed ID: 26851187
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin as novel therapy in lymphomas.
Wong BY; Dang NH
Expert Opin Biol Ther; 2010 Aug; 10(8):1251-8. PubMed ID: 20528256
[TBL] [Abstract][Full Text] [Related]
5. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.
Elkord E; Burt DJ; Sundstedt A; Nordle Ö; Hedlund G; Hawkins RE
Oncotarget; 2015 Feb; 6(6):4428-39. PubMed ID: 25669986
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.
Stan AC; Radu DL; Casares S; Bona CA; Brumeanu TD
Cancer Res; 1999 Jan; 59(1):115-21. PubMed ID: 9892195
[TBL] [Abstract][Full Text] [Related]
7. Immunoconjugates against solid tumors: mind the gap.
Ricart AD
Clin Pharmacol Ther; 2011 Apr; 89(4):513-23. PubMed ID: 21368753
[TBL] [Abstract][Full Text] [Related]
8. Antibody-targeted drugs for the therapy of cancer.
Pietersz GA; Krauer K
J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
[TBL] [Abstract][Full Text] [Related]
9. Cancer stromal targeting (CAST) therapy.
Matsumura Y
Adv Drug Deliv Rev; 2012 Jun; 64(8):710-9. PubMed ID: 22212902
[TBL] [Abstract][Full Text] [Related]
10. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
Bajaj M; Heath EI
Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
[TBL] [Abstract][Full Text] [Related]
11. Drug-conjugated monoclonal antibodies for the treatment of cancer.
Lambert JM
Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
13. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
Keir CH; Vahdat LT
Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
[TBL] [Abstract][Full Text] [Related]
14. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Ricart AD; Tolcher AW
Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
[TBL] [Abstract][Full Text] [Related]
15. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
16. Cationization of monoclonal antibodies: another step towards the "magic bullet"?
Vaisitti T; Deaglio S; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624
[TBL] [Abstract][Full Text] [Related]
17. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Multani PS; O'Day S; Nadler LM; Grossbard ML
Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
[TBL] [Abstract][Full Text] [Related]
19. Pralatrexate: basic understanding and clinical development.
Zain J; O'Connor O
Expert Opin Pharmacother; 2010 Jul; 11(10):1705-14. PubMed ID: 20509772
[TBL] [Abstract][Full Text] [Related]
20. [Immunoconjugates, drug-armed antibodies to fight against cancer].
Haeuw JF; Caussanel V; Beck A
Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
